Head and neck squamous cell carcinoma

August 25, 2023

Now Enrolling: EA3211 for Patients with Squamous Cell Carcinoma of the Head and Neck

This phase 3 study of oligometastatic head and neck cancer is exploring whether it is more effective to add radiation therapy to standard immunotherapy in patients with stable disease after initial chemotherapy plus immunotherapy
December 20, 2022

Trial Spotlight: Robert Ferris and Christine Chung on the EA3132 Trial for Patients with Head and Neck Cancer

This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck